L 651580

    WARNING: This product is for research use only, not for human or veterinary use.

Hodoodo CAT#: H559093

CAS#: 103335-44-0

Description: L 651580 is a bioactive chemical.


Chemical Structure

img
L 651580
CAS# 103335-44-0

Theoretical Analysis

Hodoodo Cat#: H559093
Name: L 651580
CAS#: 103335-44-0
Chemical Formula: C21H31NO3
Exact Mass: 345.23
Molecular Weight: 345.480
Elemental Analysis: C, 73.01; H, 9.04; N, 4.05; O, 13.89

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: L 651580; L-651580; L651580;

IUPAC/Chemical Name: methyl (4aR,4bS,6aS,7S,9aS,9bS,11aR)-1,4a,6a-trimethyl-2-oxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxylate

InChi Key: RYRGPLSUWGZYDE-ICVGDBTHSA-N

InChi Code: InChI=1S/C21H31NO3/c1-20-11-9-15-13(14(20)6-7-16(20)19(24)25-4)5-8-17-21(15,2)12-10-18(23)22(17)3/h10,12-17H,5-9,11H2,1-4H3/t13-,14-,15-,16+,17+,20-,21+/m0/s1

SMILES Code: O=C([C@H]1CC[C@]2([H])[C@]1(C)CC[C@]3([H])[C@@]4(C)C=CC(N(C)[C@]4([H])CC[C@]32[H])=O)OC

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 345.48 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Lu Q, Chen WY, Zhu ZY, Chen J, Xu YC, Kaewpet M, Rukachaisirikul V, Chen LL, Shen X. L655,240, acting as a competitive BACE1 inhibitor, efficiently decreases β-amyloid peptide production in HEK293-APPswe cells. Acta Pharmacol Sin. 2012 Dec;33(12):1459-68. doi: 10.1038/aps.2012.74. Epub 2012 Jul 30. PubMed PMID: 22842730; PubMed Central PMCID: PMC4001842.

2: Weinberg ML, Moreira E, Weinberg J. Arachidonic acid products-mediated contraction induced by bradykinin in relaxed mesenteric arterial rings from Holtzman rats. Eur J Pharmacol. 1997 Feb 12;320(2-3):145-50. PubMed PMID: 9059847.

3: Campos AH, Calixto JB. Mechanisms involved in the contractile responses of kinins in rat portal vein rings: mediation by B1 and B2 receptors. J Pharmacol Exp Ther. 1994 Feb;268(2):902-9. PubMed PMID: 8114004.

4: Tardif M, Bergeron Y, Beauchamp D, Bergeron MG. Increased renal uptake of gentamicin in endotoxemic rats receiving concomitant thromboxane A2 antagonist therapy. Antimicrob Agents Chemother. 1993 Dec;37(12):2727-32. PubMed PMID: 8109943; PubMed Central PMCID: PMC192792.

5: Llopis J, Farrell GC, Duddy SK, Kass GE, Gahm A, Orrenius S. Eicosanoids released following inhibition of the endoplasmic reticulum Ca2+ pump stimulate Ca2+ efflux in the perfused rat liver. Biochem Pharmacol. 1993 Jun 9;45(11):2209-14. PubMed PMID: 8390834.

6: Bunke M, Wilder L, Martin A. Protection of glomerular filtration rate by the thromboxane receptor antagonist L655,240 during low dose cyclosporine administration. Prostaglandins. 1992 Apr;43(4):351-60. PubMed PMID: 1535164.

7: Malcolm KC, Fitzpatrick FA. Indirect actions of thapsigargin on human platelets: activation of eicosanoid biosynthesis and cellular signaling pathways. J Pharmacol Exp Ther. 1992 Mar;260(3):1244-9. PubMed PMID: 1532033.

8: Ogletree ML, Allen GT. Interspecies differences in thromboxane receptors: studies with thromboxane receptor antagonists in rat and guinea pig smooth muscles. J Pharmacol Exp Ther. 1992 Feb;260(2):789-94. PubMed PMID: 1531361.

9: Fernandes AJ, Calvo IF, de Falco V, da Rocha FA, Sirois P, Jancar S. Mechanisms of thrombocytopenia in the acute phase of antigen-induced arthritis in rabbits. Prostaglandins. 1991 Dec;42(6):493-500. PubMed PMID: 1801060.

10: Atzori L, Olafsdóttir K, Corriga AM, Bannenberg G, Ryrfeldt A, Moldéus P. Thiol modification in H2O2- and thromboxane-induced vaso- and bronchoconstriction in rat perfused lung. J Appl Physiol (1985). 1991 Oct;71(4):1309-14. PubMed PMID: 1757354.

11: Burger R, Fung D, Bryan AC. Lung injury in a surfactant-deficient lung is modified by indomethacin. J Appl Physiol (1985). 1990 Dec;69(6):2067-71. PubMed PMID: 2077002.

12: Jones GL, Lane CG, O'Byrne PM. Effect of thromboxane antagonists on ozone-induced airway responses in dogs. J Appl Physiol (1985). 1990 Sep;69(3):880-4. PubMed PMID: 2246175.

13: Ménard L, Pilote S, Naccache PH, Laviolette M, Borgeat P. Inhibitory effects of MK-886 on arachidonic acid metabolism in human phagocytes. Br J Pharmacol. 1990 May;100(1):15-20. PubMed PMID: 2164857; PubMed Central PMCID: PMC1917464.

14: Cirino M, Morton H, MacDonald C, Hadden J, Ford-Hutchinson AW. Thromboxane A2 and prostaglandin endoperoxide analogue effects on porcine renal blood flow. Am J Physiol. 1990 Jan;258(1 Pt 2):F109-14. PubMed PMID: 2301587.

15: Hébert RL, Sirois P, Plante GE. Inhibition of platelet-activating factor induced renal hemodynamic and tubular dysfunctions with L-655,240, a new thromboxane-prostaglandin endoperoxide antagonist. Can J Physiol Pharmacol. 1989 Apr;67(4):304-8. PubMed PMID: 2758373.

16: Jancar S, Thériault P, Lauzière M, Braquet P, Sirois P. Paf-induced release of spasmogens from guinea-pig lungs. Br J Pharmacol. 1989 Jan;96(1):153-62. PubMed PMID: 2538179; PubMed Central PMCID: PMC1854309.

17: Sirois MG, Jancar S, Braquet P, Plante GE, Sirois P. PAF increases vascular permeability in selected tissues: effect of BN-52021 and L-655,240. Prostaglandins. 1988 Nov;36(5):631-44. PubMed PMID: 3238010.

18: Wainwright CL, Parratt JR. The effects of L655,240, a selective thromboxane and prostaglandin endoperoxide antagonist, on ischemia- and reperfusion-induced cardiac arrhythmias. J Cardiovasc Pharmacol. 1988 Sep;12(3):264-71. PubMed PMID: 2464097.

19: Levitt MA, Stahl G, Lefer AM. Efficacy of a combination thromboxane receptor antagonist and lipoxygenase inhibitor in traumatic shock. Resuscitation. 1988 Jul;16(3):211-20. PubMed PMID: 2845544.

20: Letts GL, McFarlane CS. Thromboxane A2 and airway responsiveness to acetylcholine aerosol in the conscious primate. Prog Clin Biol Res. 1988;263:91-8. PubMed PMID: 3380828.